MAPS in Silicon Valley: MDMA Biomarker Analysis at Stanford (Video)

Summary: Psychopharmacologist Dean Carson, Ph.D., talks about current MDMA research at Stanford University.

Originally appearing here.

Interview with Dean Carson, Ph.D., Bass Pediatric Scholar, Stanford University School of Medicine.

MAPS, a non-profit organization with administrative offices in Palo Alto and Santa Cruz, is sponsoring FDA-approved clinical research to develop psychedelic-assisted therapies into prescriptions for mental health.

On March 31, 2015, the seventh subject was enrolled in our ongoing study of MDMA-assisted therapy for social anxiety in 12 adults on the autism spectrum. This study is exploring whether MDMA combined with therapy can enhance functional skills and quality of life in autistic adults with social anxiety.

In addition to collecting data on the safety and effectiveness of MDMA-assisted therapy for reducing social anxiety in these subjects, researchers at Stanford University will also analyze blood concentrations of several hormones (oxytocin, AVP, and cortisol) hypothesized to be involved in the therapeutic effectiveness of MDMA when combined with therapy.

Sponsored by MAPS, this is a collaborative study between the MAPS Public Benefit Corporation, the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, and researchers at Stanford University.